Navigation Links
FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
Date:7/16/2014

NORTHBROOK, Ill., July 16, 2014 /PRNewswire/ -- Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection.

A product that is granted QIDP status receives a priority review and a five-year extension of market exclusivity in the United States. Previously, isavuconazole received QIDP designation for invasive aspergillosis and invasive mucormycosis (also known as zygomycosis). The incentives for all three conditions were granted under the 2012 U.S. Generating Antibiotic Incentives Now (GAIN) Act as a part of the FDA Safety and Innovation Act.

"The need to treat serious fungal infections can be one of life or death. This QIDP designation, along with the previous two we have received, emphasizes how important it is to patients and their families that products are available to treat these infections," said Bernie Zeiher, Executive Vice President, Global Development and Therapeutic Area Head of Infectious Disease at Astellas.

About Isavuconazole
Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed for the treatment of severe invasive and life-threatening fungal infections. Isavuconazole is the active moiety of the prodrug isavuconazonium sulfate. Information regarding isavuconazole ongoing clinical trials is available at clinicaltrials.gov.  

Isavuconazole demonstrated in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as activity against emerging and often fatal molds including those that cause mucormycosis.

In the Phase 3 invasive aspergillosis study, isavuco
'/>"/>

SOURCE Astellas
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Grants Orphan Drug Designation to Omeros OMS721 for Complement-Mediated Thrombotic Microangiopathies
2. FDA Grants Approval of IND to Commence a Phase 3 Pivotal Study for ST10 for the Treatment of Iron Deficiency Anaemia in Chronic Kidney Disease
3. Auxilium Pharmaceuticals, Inc. Announces Court Grants Upsher-Smith Laboratories Motion For Summary Judgment
4. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
5. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
6. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
7. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
8. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
9. Philanthropic Grants, Product Launches, Promising Partnerships, and Customer Satisfaction Rankings - Research Report on CVS Caremark, Walgreens, McKesson, AmerisourceBergen, and Cardinal Health
10. Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
11. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
(Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... No-Cost, Noninvasive Tool Detects Risk for Undiagnosed Diabetes, ... Years, ALEXANDRIA, Va., April 28 A ... undiagnosed diabetes,identify whether they likely have the disease ... and complications associated with this now,epidemic illness, according ...
... Schering-Plough Corporation,(NYSE: SGP ) today reported ... ongoing Phase II study of boceprevir, its investigational ... with chronic,hepatitis C virus (HCV) genotype 1 were ... Association for the Study of the Liver (EASL). ...
Cached Medicine Technology:Drug Combo Could Lower Diabetes Complications and Costs 2Drug Combo Could Lower Diabetes Complications and Costs 3Drug Combo Could Lower Diabetes Complications and Costs 4Drug Combo Could Lower Diabetes Complications and Costs 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., has announced ... Who and the Doors played together at the Singer Bowl ... Hawley, “The Who toured the United States heavily from 1967 ... the most famous Who poster was a poster created to ... August 2, 1968 at the Singer Bowl in Flushing, New ...
(Date:3/28/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Therapy Association Annual Conference to be held April ... in Columbus, OH. , The OPTA Annual ... with products and services. , Representatives from ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... groundbreaking new method of sustainable health. After 18 years ... of life, including professional UFC contenders, Dr. Jon Petrick ... this summer. , Just some of the immediate benefits ... energy and vitality, increased levels of strength of the ...
(Date:3/28/2015)... Virginia (PRWEB) March 28, 2015 ARDX will ... 28th from 12pm -3pm at the Chesapeake Conference Center in ... by sponsoring an empowering event for women in the Hampton ... Weaving the Stories of Women’s Lives. Women grow stronger ... from each other. This year the WWC™ theme is ...
(Date:3/28/2015)... Servpro of Paso Robles , ... report about the link between mold and asthma. Mold ... to recent medical research, may even cause asthma in ... Protection Agency, people with sensitivity to mold or mold ... trigger asthma attacks for asthma sufferers. The EPA recommends ...
Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... researchers have found that a particular resonance pattern in ... its ability to discriminate speech. ,In ... Poeppel and Huan Luo report that the inherent rhythm ... spoken sentences by changing its phase. ,The ...
... American idol winner Kelly Clarkson has revealed that she was ... interview to 'CosmoGirl!' in its August issue, the singer said ... to lose weight for a role in a play. ... thinner...then I'll get the role," Us Weekly quoted Clarkson, as ...
... wine halved in France since the 1950s, the world's number ... its saviour. But while the Chinese and Indians have ... worlds largest, there are those attending the two-yearly event who ... margins in China are not there. It is not ready ...
... a strong work ethic and sense of place appear to ... illness , in that these values may delay them from seeking ... to view their work as a lifelong endeavour, and there is ... it out or not go to the hospital, said Alex Clark, ...
... 50 years of independence this year, the fight against river ... bad news is that the parasite that causes the crippling ... one drug used to treat it. ,River blindness ... by black flies. The worms can cause intense itching, elephantiasis ...
... days is good advice for more reasons than sheer comfort. ... That's the message from the Pennsylvania Medical Society, warning young ... to be avoided at all costs - even if it ... is not an accident," says Marilyn J. Heine, M.D., an ...
Cached Medicine News:Health News:Go for Russia, Not China, Wine Experts Say 2Health News:Go for Russia, Not China, Wine Experts Say 3Health News:Rural Work Ethic Curbs Elderly Heart Care 2Health News:River Blindness Becoming Drug Resistant 2Health News:Keep a Cool Head on Hot, Humid Days to Avoid Heat Stroke 2Health News:Keep a Cool Head on Hot, Humid Days to Avoid Heat Stroke 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: